产品简要
公司名称 :
北京义翘神州
产品类型 :
蛋白
产品名称 :
SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His Recombinant Protein
目录 :
40589-V08B1
规格 :
100微克
价格 :
448美元
更多信息或购买 :
文章摘录数: 33
出版应用/物种/样本/稀释参考文献
  • 酶联免疫吸附测定; SARS冠状病毒
Acharya P, Williams W, Henderson R, Janowska K, Manne K, Parks R, et al. A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies. bioRxiv. 2020;: pubmed 出版商
  • 酶联免疫吸附测定; SARS冠状病毒
Yee J, Van Rompay K, Carpenter A, Nham P, Halley B, Iyer S, et al. SARS-CoV-2 surveillance for a non-human primate breeding research facility. J Med Primatol. 2020;: pubmed 出版商
  • 酶联免疫吸附测定; SARS冠状病毒
Lei H, Ye F, Liu X, Huang Z, Ling S, Jiang Z, et al. SARS-CoV-2 environmental contamination associated with persistently infected COVID-19 patients. Influenza Other Respir Viruses. 2020;: pubmed 出版商
Chiuppesi F, Nguyen V, Park Y, Contreras H, Karpinski V, Faircloth K, et al. Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates. NPJ Vaccines. 2022;7:7 pubmed 出版商
Hudák A, Veres G, Letoha A, Szilak L, Letoha T. Syndecan-4 Is a Key Facilitator of the SARS-CoV-2 Delta Variant's Superior Transmission. Int J Mol Sci. 2022;23: pubmed 出版商
Amanat F, Strohmeier S, Meade P, Dambrauskas N, Muhlemann B, Smith D, et al. Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus. PLoS Biol. 2021;19:e3001384 pubmed 出版商
Li J, Xu D, Wang L, Zhang M, Zhang G, Li E, et al. Glycyrrhizic Acid Inhibits SARS-CoV-2 Infection by Blocking Spike Protein-Mediated Cell Attachment. Molecules. 2021;26: pubmed 出版商
Cecon E, Burridge M, Cao L, Carter L, Ravichandran R, Dam J, et al. SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET. Cell Chem Biol. 2021;: pubmed 出版商
Garrido C, Hurst J, Lorang C, Aquino J, Rodriguez J, Pfeiffer T, et al. Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. JCI Insight. 2021;6: pubmed 出版商
Low J, Vaqueirinho D, Mele F, Foglierini M, Jerak J, Perotti M, et al. Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2. Science. 2021;372:1336-1341 pubmed 出版商
Luo S, Zhang P, Liu B, Yang C, Liang C, Wang Q, et al. Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates. Emerg Microbes Infect. 2021;10:1002-1015 pubmed 出版商
Guo Y, Huang L, Zhang G, Yao Y, Zhou H, Shen S, et al. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. Nat Commun. 2021;12:2623 pubmed 出版商
Akhter J, Quéromès G, Pillai K, Kepenekian V, Badar S, Mekkawy A, et al. The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2. Viruses. 2021;13: pubmed 出版商
Bollavaram K, Leeman T, Lee M, Kulkarni A, Upshaw S, Yang J, et al. Multiple sites on SARS-CoV-2 spike protein are susceptible to proteolysis by cathepsins B, K, L, S, and V. Protein Sci. 2021;30:1131-1143 pubmed 出版商
Zhao M, Yang W, Yang F, Zhang L, Huang W, Hou W, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021;6:134 pubmed 出版商
Ren W, Zhu Y, Wang Y, Shi H, Yu Y, Hu G, et al. Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry. PLoS Pathog. 2021;17:e1009392 pubmed 出版商
Frasca D, Reidy L, Cray C, Diaz A, Romero M, Kahl K, et al. Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients. PLoS ONE. 2021;16:e0245424 pubmed 出版商
Bläckberg A, Fernström N, Sarbrant E, Rasmussen M, Sunnerhagen T. Antibody kinetics and clinical course of COVID-19 a prospective observational study. PLoS ONE. 2021;16:e0248918 pubmed 出版商
Bertoglio F, Meier D, Langreder N, Steinke S, Rand U, Simonelli L, et al. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nat Commun. 2021;12:1577 pubmed 出版商
Nunes Santos C, Kuehn H, Rosenzweig S. N-Glycan Modification in Covid-19 Pathophysiology: In vitro Structural Changes with Limited Functional Effects. J Clin Immunol. 2021;41:335-344 pubmed 出版商
Wang D, Baudys J, Bundy J, Solano M, Keppel T, Barr J. Comprehensive Analysis of the Glycan Complement of SARS-CoV-2 Spike Proteins Using Signature Ions-Triggered Electron-Transfer/Higher-Energy Collisional Dissociation (EThcD) Mass Spectrometry. Anal Chem. 2020;92:14730-14739 pubmed 出版商
Chang A, Croix M, Kenney P, Baron S, Hicar M. Serum Responses of Children With Kawasaki Disease Against Severe Acute Respiratory Syndrome Coronavirus 2 Proteins. Pediatr Infect Dis J. 2020;39:e366-e367 pubmed 出版商
Clausen T, Sandoval D, Spliid C, Pihl J, Perrett H, Painter C, et al. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell. 2020;: pubmed 出版商
Chi X, Liu X, Wang C, Zhang X, Li X, Hou J, et al. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nat Commun. 2020;11:4528 pubmed 出版商
Gorshkov K, Susumu K, Chen J, Xu M, Pradhan M, Zhu W, et al. Quantum Dot-Conjugated SARS-CoV-2 Spike Pseudo-Virions Enable Tracking of Angiotensin Converting Enzyme 2 Binding and Endocytosis. ACS Nano. 2020;14:12234-12247 pubmed 出版商
Clausen T, Sandoval D, Spliid C, Pihl J, Painter C, Thacker B, et al. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. bioRxiv. 2020;: pubmed 出版商
Kim S, Jin W, Sood A, Montgomery D, Grant O, Fuster M, et al. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res. 2020;:104873 pubmed 出版商
Chiuppesi F, Salazar M, Contreras H, Nguyen V, Martinez J, Park S, et al. Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine. bioRxiv. 2020;: pubmed 出版商
Moriyama M, Nagai M, Maruzuru Y, Koshiba T, Kawaguchi Y, Ichinohe T. Influenza Virus-Induced Oxidized DNA Activates Inflammasomes. iScience. 2020;23:101270 pubmed 出版商
Feng S, Luan X, Wang Y, Wang H, Zhang Z, Wang Y, et al. Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein. Infect Genet Evol. 2020;85:104419 pubmed 出版商
Ravichandran S, Coyle E, Klenow L, Tang J, Grubbs G, Liu S, et al. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. Sci Transl Med. 2020;12: pubmed 出版商
Smith T, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11:2601 pubmed 出版商
Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, et al. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. Cell. 2020;182:73-84.e16 pubmed 出版商
图像
图像 1 :
北京义翘神州 40589-V08B1 图像 1
产品信息
提示 :
Online
目录代码 :
40589-V08B1
产品名称 :
SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His Recombinant Protein
产品类型 :
蛋白
宿主物种 :
杆状病毒昆虫细胞
共轭 :
C多聚组氨酸
规格 :
100微克
标价 :
448美元
基因编号 :
YP_009724390.1
产品描述 :
A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Spike Protein (S1+S2 ECD) (YP_009724390.1) (Val 16-Pro1213) was expressed with a polyhistidine tag at the C-terminus.
物种摘要 :
SARS-CoV-2
别名 :
Spike
特异性 :
The 2019-nCoV Spike Protein (S1+S2 ECD, His tag) can bind with Human ACE2 in functional ELISA assay.
纯度 :
> 90 % as determined by SDS-PAGE.
缓冲液 :
Lyophilized from sterile 20 mM Tris, 300 mM NaCl, 10 % glycerol, pH 8.0.
包装 :
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
储存 :
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
更多信息或购买 :
公司信息
北京义翘神州
北京市北京经济技术开发区科创十街18号院9号楼
Order@Sinobiological.com
http://www.sinobiological.cn
400-890-9989
公司总部: 中国
北京义翘神州科技股份有限公司(Sino Biological Inc.)是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司,主要业务有重组蛋白、抗体、基因和培养基等产品,以及重组蛋白、抗体的开发和生物分析检测等服务。

义翘科技为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。义翘科技目前生产和销售的现货产品种类超过4.6万种,能够全面满足客户对于最接近人体天然蛋白结构和性质的重组蛋白需求,并覆盖生命科学研究的多个领域,为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供“一站式”生物试剂产品和技术服务。

义翘科技的客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲建立了子公司,累计客户数量超过5,000个,品牌声誉不断累积,已成为生物试剂行业国内领先的科技公司之一。